RBBP4 Enhances Platinum Chemo Resistance in Lung Adenocarcinoma
Background. The majority of lung cancers are adenocarcinomas, with the proportion being 40%. The patients are mostly diagnosed in the middle and late stages with metastasis and easy recurrence, which poses great challenge to the treatment and prognosis. Platinum-based chemotherapy is a primary treat...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Hindawi Limited
2021-01-01
|
| Series: | BioMed Research International |
| Online Access: | http://dx.doi.org/10.1155/2021/6905985 |